Covishield, India’s first COVID-19 vaccine is approved and is safe, effective and ready for roll-out: SII CEO

New Delhi: Serum Institute of India Chief Executive Officer Adar Poonawalla on Sunday said that Covishield, India’s first COVID-19 vaccine is approved and is safe, effective and ready for roll-out in the coming weeks.

Taking to Twitter, Poonawalla said, “Happy new year, everyone! All the risks @SerumInstIndia took with stockpiling the vaccine have finally paid off. COVISHIELD, India’s first COVID-19 vaccine is approved, safe, effective, and ready to roll-out in the coming weeks.”

He also thanked the political leadership, including Prime Minister Narendra Modi, Union Health Minister Dr Harsh Vardhan and Drugs Controller General of India (DCGI).

“Thank you Hon. Sri @narendramodi Ji, Hon. Sri @drharshvardhan Ji, @MoHFW_INDIA @ICMRDELHI

@DBTIndia #DCGI_India@UniofOxford @AstraZeneca @gavi @GaviSeth @gatesfoundation and @BillGates for your support, @drharshvardhan ji, thank you for launching PNEUMONSIL, manufactured by @SerumInstIndia, the first made-in-India vaccine to prevent the disease of Pneumonia in children. Thank you @MoHFW_INDIA @gatesfoundation @PATHtweets and especially @BillGates,” he tweeted.

He also thanked Bill and Melinda Gates Foundation.

Earlier today, COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in an emergency situation, said Drugs Controller General of India (DCGI).

“After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial,” said VG Somani, DCGI, during a media briefing today.

The post Covishield, India’s first COVID-19 vaccine is approved and is safe, effective and ready for roll-out: SII CEO appeared first on NewsroomPost.



from NewsroomPost https://ift.tt/2X4OIOX
https://ift.tt/eA8V8J

Comments